Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0172 | 0.5 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0172 | 0.5 | 0.5 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0172 | 0.5 | 0.5 |
Echinococcus granulosus | proteasome prosome macropain | 0.0172 | 0.5 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0172 | 0.5 | 0.5 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0172 | 0.5 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0172 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0172 | 0.5 | 0.5 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0172 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0172 | 0.5 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0172 | 0.5 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0172 | 0.5 | 0.5 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0172 | 0.5 | 0.5 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0172 | 0.5 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0172 | 0.5 | 0.5 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0172 | 0.5 | 0.5 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0172 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
F (ADMET) | = 17 % | Oral bioavailability in mouse | ChEMBL. | 20925433 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.